This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Flumatinib
- DrugBank Accession Number
- DB11904
- Background
Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Flumatinib (DB11904)
- Weight
- Average: 562.601
Monoisotopic: 562.241642075 - Chemical Formula
- C29H29F3N8O
- Synonyms
- Not Available
- External IDs
- HH-GV678
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Flumatinib. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Flumatinib. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Flumatinib. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Flumatinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Flumatinib. Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Flumatinib. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Flumatinib. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Flumatinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Flumatinib. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Flumatinib Mesylate 95Y8L63NBC 895519-91-2 ZSASDYCFROUKTJ-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyridinylpyrimidines
- Alternative Parents
- Trifluoromethylbenzenes / Benzamides / Phenylmethylamines / Benzylamines / Benzoyl derivatives / Aminopyridines and derivatives / Aminopyrimidines and derivatives / N-methylpiperazines / Methylpyridines / Aralkylamines show 10 more
- Substituents
- 1,4-diazinane / Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aminopyridine / Aminopyrimidine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R4009Y24AI
- CAS number
- 895519-90-1
- InChI Key
- BJCJYEYYYGBROF-UHFFFAOYSA-N
- InChI
- InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
- IUPAC Name
- N-(6-methyl-5-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide
- SMILES
- CN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)N=C2)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 46848036
- PubChem Substance
- 347828237
- ChemSpider
- 25069687
- ChEMBL
- CHEMBL3545413
- ZINC
- ZINC000068244727
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Chronic Phase Chronic Myeloid Leukemia 1 4 Recruiting Treatment Acute Leukemia 1 4 Recruiting Treatment Chronic Phase Chronic Myeloid Leukemia 2 4 Recruiting Treatment Chronic Phase Chronic Myeloid Leukemia / Flumatinib / Imatinib 1 3 Completed Treatment CML, CML-CP,MMR,TKI 1 3 Recruiting Treatment Acute Lymphocytic Leukemia, Adult B-Cell / BCR-ABL1 Fusion Protein Expression 1 2 Recruiting Treatment Acute Lymphoblastic Leukemia (ALL) / Acute Myeloid Leukemia / Chronic Myelogenous Leukemia (CML) / Mixed Phenotype Acute Leukemia (MPAL) / Philadelphia Chromosome 1 2 Unknown Status Treatment Chronic Myelogenous Leukemia (CML) 2 Not Available Recruiting Not Available CML, Chronic Phase; TKI 1 Not Available Recruiting Not Available CML-CP; Mutation;Suboptimal Response or Failure in TKI 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0102 mg/mL ALOGPS logP 3.43 ALOGPS logP 3.66 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 11.21 Chemaxon pKa (Strongest Basic) 7.57 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 99.17 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 152.3 m3·mol-1 Chemaxon Polarizability 57.44 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 20:59 / Updated at June 12, 2020 16:53